AKT1 and anaplastic large cell lymphoma: As a matter of fact, our group previously discovered activation of RAS/MAPK and PI3K/AKT pathways as off-target resistance mechanisms to lorlatinib in a preclinical model of ALCL (i.e., AS4 cell line).